Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a large decline in short interest during the month of June. As of June 30th, there was short interest totaling 155,235 shares, a decline of 40.4% from the June 15th total of 260,360 shares. Currently, 5.0% of the shares of the stock are short sold. Based on an average daily volume of 252,050 shares, the days-to-cover ratio is currently 0.6 days.
Valion Bio, Inc. Common Stock Trading Up 8.3%
Shares of VBIO stock opened at $0.49 on Friday. Valion Bio, Inc. Common Stock has a twelve month low of $0.40 and a twelve month high of $5.60. The stock’s fifty day simple moving average is $0.68 and its 200 day simple moving average is $0.92. The company has a quick ratio of 3.02, a current ratio of 3.31 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $1.56 million, a P/E ratio of -0.07 and a beta of 1.82.
Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) last posted its earnings results on Thursday, May 14th. The company reported ($2.23) EPS for the quarter.
Analyst Upgrades and Downgrades
View Our Latest Research Report on Valion Bio, Inc. Common Stock
Valion Bio, Inc. Common Stock Company Profile
Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.
The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.
See Also
- Five stocks we like better than Valion Bio, Inc. Common Stock
- J.B. Hunt Stock Could Reach $340 as Trucking Capacity Shrinks
- The AI Data Center Boom Is Bigger Than One Stock—These ETFs Spread the Bet
- Palantir’s Wild Ride: Inside the Stock Wall Street Can’t Agree On
- Has Broadcom Become Too Expensive for Its AI Story?
Receive News & Ratings for Valion Bio Inc. Common Stock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valion Bio Inc. Common Stock and related companies with MarketBeat.com's FREE daily email newsletter.
